Dear Mr. Winick:

Please refer to your Supplemental New Drug Applications (sNDA’s) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

<table>
<thead>
<tr>
<th>NDA #</th>
<th>Supplement #</th>
<th>Submission Date</th>
<th>Name of Drug Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>21-085</td>
<td>050</td>
<td>March 25, 2011</td>
<td>AVELOX (moxifloxacin hydrochloride) Tablets</td>
</tr>
<tr>
<td></td>
<td>053</td>
<td>August 16, 2011</td>
<td></td>
</tr>
<tr>
<td>21-277</td>
<td>046</td>
<td>March 25, 2011</td>
<td>AVELOX (moxifloxacin hydrochloride) IV</td>
</tr>
<tr>
<td></td>
<td>050</td>
<td>August 16, 2011</td>
<td></td>
</tr>
</tbody>
</table>

We acknowledge receipt of your amendments dated August 1, and October 7, 2011, to NDA 21-085/S-050 and NDA 21-277/S-046.

The March 25, 2011, “Prior Approval” labeling supplemental new drug applications provide for revisions to the package insert to change information for *in vitro* susceptibility test interpretive criteria (breakpoints) and quality control (QC) parameters for the *in vitro* susceptibility testing of organisms listed in the package insert.
The August 16, 2011, “Prior Approval” labeling supplemental new drug applications provide for the addition of ‘pseudotumor cerebri’ to the WARNINGS AND PRECAUTIONS section, Central Nervous System Effects/Disorders subsection of the package insert along with minor editorial changes as follows:

“Fluoroquinolones, including AVELOX, may cause central nervous system (CNS) events, including: nervousness, agitation, insomnia, anxiety, nightmares or paranoia.

“Convulsions and increased intracranial pressure (including pseudotumor cerebri) have been reported in patients receiving fluoroquinolones. Fluoroquinolones may also cause central nervous system (CNS) events including: dizziness, confusion, tremors, hallucinations, depression, and, rarely, suicidal thoughts or acts.”

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).
REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Fariba Izadi, Pharm.D., Regulatory Project Manager, at (301) 796-0563.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Deputy Director for Safety
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
10/18/2011